Specialized Formulation CDMO Integrity Bio's core capabilities in formulation development and GMP filling for biologics position it well for clients seeking end-to-end CDMO services, including hard-to-formulate liquids and lyophilized products. Leverage track record of formulating a diverse biologics portfolio to win projects from biotechs seeking specialized formulation expertise, accelerated timelines, and robust regulatory-compliant processes.

Proprietary Formulation Tech Integrity Bio’s proprietary LyoTip and EXCELSE technologies offer competitive differentiation by enabling one-step reconstitution and ready-to-use subcutaneous dosing, reducing handling complexity and time-to-dose. This presents cross-sell opportunities to clients with lyophilized vaccines, antibodies, or IV drugs seeking improved stability, ease of administration, and potential manufacturing scale-up.

Acquisition Context With Integrity Bio now part of Curia, the company benefits from a broader global CDMO network and client base. This allows leveraging Curia relationships to expand into additional biologics programs and to offer integrated services across formulation, fill-finish, and regulatory support.

Target Client Segments The company serves biotech and pharma clients developing vaccines, antibodies, proteins, and peptides, with capability for liquid and lyophilized formulations. Prioritize proximity-led outreach to West Coast clusters and pursue pilot programs with growth-stage biotechs seeking faster formulation and GMP fill-finish for complex biologics.

Growth Through Partnerships Position Integrity Bio as a specialized partner for long-term development and manufacturing programs within the Curia ecosystem, pursuing co-development and capacity-enabled deals that leverage LyoTip and EXCELSE across diverse therapies to win larger, multi-year contracts.